• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/4/23 1:31:18 PM ET
    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Medical Electronics
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFLY alert in real time by email

    Gainers

    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares increased by 29.2% to $6.06 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 35.0 million, which is 6710.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $34.2 million.
    • Assure Hldgs (NASDAQ:IONM) shares increased by 27.68% to $3.92. As of 13:30 EST, this security is trading at a volume of 986.5K shares, making up 1876.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.3 million. As per the press release, Q4 earnings came out yesterday.
    • Clearside Biomedical (NASDAQ:CLSD) stock rose 27.1% to $1.36. The current volume of 1.0 million shares is 507.6% of Clearside Biomedical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $83.4 million.
    • Corvus Pharma (NASDAQ:CRVS) stock increased by 25.55% to $1.25. Trading volume for this security as of 13:30 EST is 1.2 million, which is 1010.7% of its average full-day volume over the last 100 days. The company's market cap stands at $58.1 million.
    • Butterfly Network (NYSE:BFLY) stock moved upwards by 18.68% to $2.22. Trading volume for Butterfly Network's stock is 34.5 million as of 13:30 EST. This is 1912.0% of its average full-day volume over the last 100 days. The company's market cap stands at $451.5 million.
    • Ocuphire Pharma (NASDAQ:OCUP) stock increased by 18.18% to $5.33. Trading volume for Ocuphire Pharma's stock is 626.1K as of 13:30 EST. This is 518.0% of its average full-day volume over the last 100 days. The company's market cap stands at $111.6 million. The company's, Q4 earnings came out 3 days ago.

    Losers

    • Oncternal Therapeutics (NASDAQ:ONCT) stock decreased by 59.2% to $0.32 during Tuesday's regular session. Trading volume for Oncternal Therapeutics's stock is 7.3 million as of 13:30 EST. This is 2782.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.9 million.
    • Lannett (NYSE:LCI) stock declined by 48.67% to $0.96. Trading volume for this security as of 13:30 EST is 793.9K, which is 1096.0% of its average full-day volume over the last 100 days. The company's market cap stands at $10.3 million.
    • GlucoTrack (NASDAQ:GCTK) stock fell 35.86% to $0.24. The current volume of 61.4K shares is 383.8% of GlucoTrack's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $3.7 million.
    • Kiromic BioPharma (NASDAQ:KRBP) stock declined by 28.89% to $3.52. Trading volume for this security as of 13:30 EST is 209.4K, which is 185.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.4 million.
    • Petros Pharmaceuticals (NASDAQ:PTPI) stock decreased by 23.08% to $1.0. Petros Pharmaceuticals's stock is trading at a volume of 122.1K shares as of 13:30 EST. This is 745.5% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 million.
    • G Medical Innovations (NASDAQ:GMVD) stock decreased by 14.52% to $0.62. As of 13:30 EST, this security is trading at a volume of 646.6K shares, making up 56.5% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY
    $BFRG
    $CLSD
    $CRVS

    CompanyDatePrice TargetRatingAnalyst
    Corvus Pharmaceuticals Inc.
    $CRVS
    10/13/2025$16.00Overweight
    Barclays
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025$2.00Buy → Hold
    Stifel
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    Clearside Biomedical Inc.
    $CLSD
    7/18/2025Buy → Neutral
    H.C. Wainwright
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    Butterfly Network Inc.
    $BFLY
    3/17/2025Outperform
    William Blair
    Corvus Pharmaceuticals Inc.
    $CRVS
    1/2/2025$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    SEC Filings

    View All

    SEC Form 10-K filed by Bullfrog AI Holdings Inc.

    10-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    3/19/26 4:45:34 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

    SCHEDULE 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/17/26 4:20:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    GlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Glucotrack, Inc. (0001506983) (Filer)

    3/13/26 4:05:32 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Devivo Joseph sold $1,788,291 worth of shares (482,149 units at $3.71), decreasing direct ownership by 6% to 8,030,899 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/6/26 4:05:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    EVP, CFO Doherty John N. was granted 274,953 shares, increasing direct ownership by 22% to 1,509,641 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/4/26 4:13:21 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Chief Technology Officer Ku Victor was granted 287,326 shares, increasing direct ownership by 35% to 1,099,288 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/4/26 4:12:16 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended De

    3/12/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BullFrog to Host Webinar on New Precision AI Capability

    GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence ("AI") and machine learning to turn complex biomedical data into actionable insights, will host a webinar in partnership with Xtalks Life Sciences, "Turning AI Recommendations into Clear, Defensible Decisions", about BullFrog AI's new precision AI capability on Friday, March 27, 2026 at 11 a.m. ET. The new AI capability advances the Company's end-to-end intelligence workflow by adding a strategic decision support layer on top of existing platforms bfPREP™ and bfLEAP®. Unlike traditional portfolio tools t

    3/11/26 8:00:00 AM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Corvus Pharmaceuticals with a new price target

    Barclays initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $16.00

    10/13/25 8:52:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butterfly Network downgraded by Oppenheimer

    Oppenheimer downgraded Butterfly Network from Outperform to Perform

    8/1/25 12:44:19 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Clearside Biomedical downgraded by Stifel with a new price target

    Stifel downgraded Clearside Biomedical from Buy to Hold and set a new price target of $2.00

    7/18/25 8:10:27 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

    RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Usman Latif, MD, MBA, has been named to Glucotrack's clinical advisory team, providing strategic counsel as the Company advances its epidural glucose monitoring applications alongside its continuous blood glucose monitor (CBGM). "Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of Painful Diabetic Neuropathy (PDN). His exceptional knowledge in pain man

    10/29/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/13/24 11:14:05 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiromic BioPharma Inc.

    SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)

    11/4/24 7:38:30 PM ET
    $KRBP
    Medicinal Chemicals and Botanical Products
    Health Care

    $BFLY
    $BFRG
    $CLSD
    $CRVS
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on February 26 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor

    2/3/26 8:01:00 AM ET
    $BFLY
    Medical Electronics
    Health Care